Efficacy and safety of topiramate in refractory epilepsy of childhood: Long-term follow-up study

Journal of Child Neurology

Volumn 20, Issue 11, 2005, Pages 893-897

  Grosso, Salvatore ^a   Franzoni, Emilio ^b   Iannetti, Paola ^c   Incorpora, Gemma ^d   Cardinali, Cesare ^e   Toldo, Irene ^f   Verrotti, Alberto ^g   Moscano, Filomena Caterina ^b   Lo Faro, Valentina ^c   Mazzone, Luigi ^d   Zamponi, Nelia ^e   Boniver, Clementina ^f   Spalice, Alberto ^c   Parisi, Pasquale ^c   Morgese, Guido ^a   Balestri, Paolo ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e Ospedale Pediatrico G Salesi   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; TOPIRAMATE; VALPROIC ACID;

ACUTE PSYCHOSIS; ADD ON THERAPY; ADOLESCENT; AGGRESSIVENESS; ANALYSIS OF VARIANCE; ANOREXIA; ARTICLE; ATTENTION DISTURBANCE; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CHILD; CLINICAL FEATURE; DESQUAMATION; DISEASE SEVERITY; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RETENTION; DRUG SAFETY; ELECTROENCEPHALOGRAM; EPILEPSY; FEMALE; FOLLOW UP; GENERALIZED EPILEPSY; GLAUCOMA; HAND DISEASE; HUMAN; HYPERTHERMIA; INFANT; INFANTILE SPASM; ITALY; LENNOX GASTAUT SYNDROME; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; METABOLIC ACIDOSIS; NEPHROLITHIASIS; NERVOUSNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPEN STUDY; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK REDUCTION; SEDATION; SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIDEORECORDING; WECHSLER INTELLIGENCE SCALE; WEIGHT REDUCTION;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 31144438237     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738050200110601     Document Type: Article

References (36)

1. Faught E, Wilder BJ, Ramsay RE, et al: Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-,400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996;46:1684-1690.
2. Ben-Menachem E, Henriksen O, Dam M, et al: Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-543.
3. Elterman RD, Glauser TA, Wyllie E, et al: A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 1999;22:1338-1344.
4. Coppola G, Caliendo G, Terracciano MM, et al: Topiramate in refractory partial-onset seizures in children, adolescents and young adults: A multicentric open trial. Epilepsy Res 2001; 43:255-260.
5. Reife RA, Pledger GW: Topiramate as adjunctive therapy in refractory partial epilepsy: Pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia 1997;38(Suppl 1):S31-3.
6. Christensen J, Andreasen F, Poulsen JH, Dam M: Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy. Neurology 2003;61:1210-1218.
7. Biton V, Montouris GD, Ritter F, et al: Randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;22: 1330-1337.
8. Glauser TA, Clark PO, Strawsburg R: A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998;39:1324-1328.
9. Glauser TA, Clark PO, McGee K: Long-term response to topiramate in patients with West syndrome. Epilepsia 2000;41(Suppl 1):S91-S94.
10. Jayawant S, Libretto SE: Topiramate in the treatment of myoclonicastatic epilepsy in children: A retrospective hospital audit. J Postgrad Med 2003;49:202-205.
11. Coppola G, Capovilla G, Montagnini A, et al: Topiramate as add-on drug in severe myoclonic epilepsy in infancy: An Italian multicenter open trial. Epilepsy Res 2002;49:45-48.
12. Bensalem MK, Fakhoury TA: Topiramate and status epilepticus: Report of three cases. Epilepsy Behav 2003;4:757-760.
13. Kahriman M, Minecan D, Kutluay E, et al: Efficacy of topiramate in children with refractory status epilepticus. Epilepsia 2003;44:1353-1356.
14. Sachdeo RC, Glauser TA, Ritter F, et al: A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;10:1882-1887.
15. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC: Topiramate in Lennox-Gastaunt syndrome: Open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000;41(Suppl 1):S86-S90.
16. Hancock E, Cross H: Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003(3):CD003277.
17. Commission on Classification and Terminology of the International League Against Epilepsy, 1981: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia, 1981;22:489-501.
18. Commission on Classification and Terminology of the International League Against Epilepsy, 1989: Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia, 1989;30:389-399.
19. Mikaeloff Y, de Saint-Martin A, Mancini J, et al: Topiramate: Efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003;53:225-232.
20. Moreland EC, Griesemer DA, Holden KR: Topiramate for intractable childhood epilepsy. Seizure 1999;8:38-40.
21. Yeung S, Ferrie CD, Murdoch-Eaton DG, Livingston JH: Topiramate for drug-resistant epilepsies. Eur J Paediatr Neurol 2000;4:31-33.
22. Mohamed E, Appleton R, Rosenbloom L: Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: A clinical experience. Seizure 2000;9:137-141.
23. Uldall P, Buchholt JM: Clinical experiences with topiramate in children with intractable epilepsy. Eur J Paediatr Neurol 1999;3: 105-111.
24. Wheless JW: Use of topiramate in childhood generalized seizure disorders. J Child Neurol 2000;15(Suppl 1):S7-S13.
25. Reith D, Burke C, Appleton DB, et al: Tolerability of topiramate in children and adolescents. J Paediatr Child Health 2003;39: 416-419.
26. Kellett MW, Smith DF, Stockton PA, Chadwick DW: Topiramate in clinical practice: First year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999;66: 759-763.
27. Demir E, Aysun S: Weight gain associated with valproate in childhood. Pediatr Neurol 2000;22:361-364.
28. Shorvon SD: Safety of topiramate: Adverse events and relationships to dosing. Epilepsia 1996;37(Suppl 2):S18-S22.
29. Mula M, Trimble MR, Lhatoo SD, Sander JW: Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003;44:659-663.
30. Levisohn PM: Safety and tolerability of topiramate in children. J Child Neurol 2000; 15(Suppl 1):S22-S26.
31. Fraunfelder FW, Fraunfelder FT, Keates EU: Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology 2004;111:109-111.
32. Philippi H, Boor R, Reitter B: Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002;43:744-747.
33. Longin E, Teich M, Koelfen W, Konig S: Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia 2002;43:1110.
34. de Carolis P Magnifico F, Pierangeli G, et al: Transient hypohidrosis induced by topiramate. Epilepsia 2003;44:974-976.
35. Ben-Zeev B, Watemberg N, Augarten A, et al: Oligohydrosis and hyperthermia: Pilot study of a novel topiramate adverse effect. J Child Neurol 2003;18:254-257.
36. Arcas J, Ferrer T, Roche MC, Martinez-Bermejo A, et al: Hypohidrosis related to the administration of topiramate to children. Epilepsia 2001;42:1363-1365.